Abstract
There is growing evidence to suggest that chronic, low-grade inflammation occurs in abdominal obesity, insulin resistance, type 2 diabetes mellitus and related complications, and that proinflammatory cytokines play an important role in the onset and progression of type 2 diabetes. These findings consequently provide new opportunities for the use of anti-inflammatory strategies to correct the metabolic disorders. Discovery of new synthetic bioactive small molecules to interfere with chronic, low-grade inflammation and type 2 diabetes has attracted considerable attention in medicinal chemistry. To date, a number of organoselenium small molecules and chromium(III) complexes have been shown to have the potential to alleviate chronic low-grade inflammation and type 2 diabetes, including ebselen, selenomethionine, chromium picolinate, chromium dinicocysteinate, chromium phenylalaninate, trinuclear chromium propionate, chromium histidinate, chromium nicotinate, etc. Here, we review recent advances in development of organoselenium small molecules and chromium(III) complexes to intervene in chronic low-grade inflammation and type 2 diabetes, and discuss their mode of action, potential molecular mechanisms and toxicity.
Keywords: Chromium, Diabetes, Ebselen, Inflammation, Insulin resistance, Pancreatic β-cells, Selenium.
Current Topics in Medicinal Chemistry
Title:Organoselenium Small Molecules and Chromium(III) Complexes for Intervention in Chronic Low-grade Inflammation and Type 2 Diabetes
Volume: 16 Issue: 8
Author(s): Jun Zhou, Huibi Xu and Kaixun Huang
Affiliation:
Keywords: Chromium, Diabetes, Ebselen, Inflammation, Insulin resistance, Pancreatic β-cells, Selenium.
Abstract: There is growing evidence to suggest that chronic, low-grade inflammation occurs in abdominal obesity, insulin resistance, type 2 diabetes mellitus and related complications, and that proinflammatory cytokines play an important role in the onset and progression of type 2 diabetes. These findings consequently provide new opportunities for the use of anti-inflammatory strategies to correct the metabolic disorders. Discovery of new synthetic bioactive small molecules to interfere with chronic, low-grade inflammation and type 2 diabetes has attracted considerable attention in medicinal chemistry. To date, a number of organoselenium small molecules and chromium(III) complexes have been shown to have the potential to alleviate chronic low-grade inflammation and type 2 diabetes, including ebselen, selenomethionine, chromium picolinate, chromium dinicocysteinate, chromium phenylalaninate, trinuclear chromium propionate, chromium histidinate, chromium nicotinate, etc. Here, we review recent advances in development of organoselenium small molecules and chromium(III) complexes to intervene in chronic low-grade inflammation and type 2 diabetes, and discuss their mode of action, potential molecular mechanisms and toxicity.
Export Options
About this article
Cite this article as:
Zhou Jun, Xu Huibi and Huang Kaixun, Organoselenium Small Molecules and Chromium(III) Complexes for Intervention in Chronic Low-grade Inflammation and Type 2 Diabetes, Current Topics in Medicinal Chemistry 2016; 16 (8) . https://dx.doi.org/10.2174/1568026615666150827094815
DOI https://dx.doi.org/10.2174/1568026615666150827094815 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Influence of Diabetes Mellitus on Rotator Cuff Repair: A Systematic Review and Meta-Analysis
Combinatorial Chemistry & High Throughput Screening Prospects of Molecularly-Targeted Therapies for Cervical Cancer Treatment
Current Drug Targets Development of Scaffolds for Vascular Tissue Engineering: Biomaterial Mediated Neovascularization
Current Stem Cell Research & Therapy Polyphenols in Disease: from Diet to Supplements
Current Pharmaceutical Biotechnology Genetic Polymorphism and Tumor Immunotherapy
Current Pharmacogenomics Antiplatelet Treatment in Peripheral Arterial Disease: The Role of Novel Antiplatelet Agents
Current Pharmaceutical Design The Management of Phosphodiesterase-5 (PDE5) Inhibitor Failure
Current Vascular Pharmacology Investigating Parent of Origin Effects in Studies of Type 2 Diabetes and Obesity
Current Diabetes Reviews The MHC Genes in Psoriasis
Current Genomics Correlation Between ROS Production and InsP3 Released by Granulocytes from Type 1 Diabetic Patients in a cAMP-Dependent Manner
Current Aging Science Cell-Penetrating Peptides as a Potential Drug Delivery System for Effective Treatment of Diabetes
Current Pharmaceutical Design Editorial [Hot topic: Adipocytokines in Nonalcoholic Fatty Liver Disease: Key Players Regulating Steatosis, Inflammation and Fibrosis (Executive Editor: Herbert Tilg)]
Current Pharmaceutical Design Multiple Pregnancies After ART and How to Minimize their Occurrence
Current Women`s Health Reviews Emerging Concepts in the Pathogenesis and Treatment of Polycystic Ovary Syndrome
Current Women`s Health Reviews Omega-3 Fatty Acids: Role in Metabolism and Cardiovascular Disease
Current Pharmaceutical Design Metabolomics Applications in Precision Medicine: An Oncological Perspective
Current Topics in Medicinal Chemistry The Treatment of Cardiovascular Disease Continuum: Focus on Pharmacologic Management and RAS Blockade
Current Clinical Pharmacology Personalized Diabetes and Cancer Medicine: A Rationale for Anti-Diabetic Nutrition (Bitter Melon) in a Supportive Setting
Current Cancer Therapy Reviews Premature Ageing Prevention: Limitations and Perspectives of Pharmacological Interventions
Current Drug Targets Assessment of Glomerular and Tubular Function
Current Pediatric Reviews